Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FOLD
stocks logo

FOLD

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
146.68M
+15.8%
--
--
164.24M
+16.06%
--
--
182.46M
+21.88%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Amicus Therapeutics, Inc. (FOLD) for FY2025, with the revenue forecasts being adjusted by -1.5% over the past three months. During the same period, the stock price has changed by -11.18%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.5%
In Past 3 Month
Stock Price
Go Down
down Image
-11.18%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast FOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 17.00 USD with a low forecast of 13.00 USD and a high forecast of 22.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 5.960
sliders
Low
13.00
Averages
17.00
High
22.00
up Image0
Current: 5.960
sliders
Low
13.00
Averages
17.00
High
22.00
Morgan Stanley
Equal Weight -> Overweight
upgrade
$12
2025-07-16
New
Reason
Morgan Stanley
Price Target
$12
2025-07-16
New
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded Amicus to Overweight from Equal Weight with a $12 price target.
Morgan Stanley
Morgan Stanley
Equal Weight -> Overweight
upgrade
$102 -> $108
2025-07-16
New
Reason
Morgan Stanley
Morgan Stanley
Price Target
$102 -> $108
2025-07-16
New
upgrade
Equal Weight -> Overweight
Reason
Morgan Stanley upgraded Amicus to Overweight from Equal Weight with a price target of $108, up from $102. The firm said it the upgrade is based on its favorable view of Amicus' intellectual property position heading into summary judgment with Aurobindo and longer term confidence in patients switching from Nexviazyme/Lumizyme to PomOp. The firm also noted that the Q1 miss was driven by order timing and the higher UK Voluntary Scheme for Branded Medicines Pricing and Access rebate rate of 22%, compared to the anticipated 12%-15%, reflected in the updated guidance.
Needham
Gil Blum
Hold
Reiterates
n/a
2025-02-20
Reason
Needham
Gil Blum
Price Target
n/a
2025-02-20
Reiterates
Hold
Reason
Wells Fargo
Tiago Fauth
Buy
Maintains
$18 → $17
2025-02-20
Reason
Wells Fargo
Tiago Fauth
Price Target
$18 → $17
2025-02-20
Maintains
Buy
Reason
Wells Fargo analyst Tiago Fauth lowered the firm's price target on Amicus to $17 from $18 and keeps an Overweight rating on the shares. The firm notes the company reported fairly in-line earnings, with no material updates vs pre-announcement. PomOp launch remains the focus of the stock and Amicus continues to execute well with Australia approval recently granted.
Cantor Fitzgerald
Kristen Kluska
Buy
Reiterates
$21
2025-01-15
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$21
2025-01-15
Reiterates
Buy
Reason
Needham
Gil Blum
Hold
Reiterates
n/a
2025-01-13
Reason
Needham
Gil Blum
Price Target
n/a
2025-01-13
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Amicus Therapeutics Inc (FOLD.O) is -122.13, compared to its 5-year average forward P/E of -1.75. For a more detailed relative valuation and DCF analysis to assess Amicus Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.75
Current PE
-122.13
Overvalued PE
121.60
Undervalued PE
-125.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
36.79
Current EV/EBITDA
26.18
Overvalued EV/EBITDA
183.60
Undervalued EV/EBITDA
-110.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
7.97
Current PS
2.96
Overvalued PS
11.39
Undervalued PS
4.56

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

FOLD News & Events

Events Timeline

(ET)
2025-06-25
07:08:43
Amicus announces approval of Pombiliti + Opfolda in Japan
select
2025-06-03 (ET)
2025-06-03
07:06:10
Amicus announces publication of post-hoc analysis of data from PROPEL study
select
2025-05-01 (ET)
2025-05-01
07:07:12
Amicus lowers FY25 total revenue growth view 15%-22% from 17%-24%
select
Sign Up For More Events
Sign Up For More Events

News

Preview
6.0
07-17SeekingAlpha
Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching

  • Stock Upgrade: Amicus Therapeutics' stock was upgraded by Morgan Stanley from Equal Weight to Overweight, with a price target suggesting nearly 100% upside, due to favorable conditions ahead of a patent ruling against Aurobindo and potential growth from its Pompe disease therapy, Pom-Op.

  • Patent Dispute and Market Potential: The upgrade is supported by an ongoing lawsuit regarding patent infringement related to Amicus's Fabry disease therapy, Galafold, and the anticipated patient transition to Pom-Op from competing treatments.

Preview
7.0
07-10PRnewswire
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

  • Investigation Announcement: Kaskela Law LLC is investigating Amicus Therapeutics, Inc. due to a significant decline in its stock value, which has dropped over 32% this year, currently trading below $7.00 per share.

  • Shareholder Rights: The investigation aims to determine potential violations of securities laws or breaches of fiduciary duties by the company's officers and directors, encouraging shareholders to contact Kaskela Law for information on their legal rights.

Preview
9.0
06-25Newsfilter
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

  • Approval of New Treatment: Amicus Therapeutics announced that Japan's Ministry of Health has approved Pombiliti (cipaglucosidase alfa) in combination with Opfolda (miglustat) for treating adult patients with late-onset Pompe disease, expanding its availability to multiple countries including the U.S. and E.U.

  • Therapeutic Details: The two-component therapy aims to enhance enzyme uptake in muscle cells and stabilize the enzyme in the blood, addressing severe symptoms associated with late-onset Pompe disease, which leads to progressive muscle weakness.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Amicus Therapeutics Inc (FOLD) stock price today?

The current price of FOLD is 5.96 USD — it has decreased -5.25 % in the last trading day.

arrow icon

What is Amicus Therapeutics Inc (FOLD)'s business?

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

arrow icon

What is the price predicton of FOLD Stock?

Wall Street analysts forecast FOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 17.00 USD with a low forecast of 13.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Amicus Therapeutics Inc (FOLD)'s revenue for the last quarter?

Amicus Therapeutics Inc revenue for the last quarter amounts to 125.25M USD, increased 13.45 % YoY.

arrow icon

What is Amicus Therapeutics Inc (FOLD)'s earnings per share (EPS) for the last quarter?

Amicus Therapeutics Inc. EPS for the last quarter amounts to -0.07 USD, decreased -56.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Amicus Therapeutics Inc (FOLD)'s fundamentals?

The market is revising Downward the revenue expectations for Amicus Therapeutics, Inc. (FOLD) for FY2025, with the revenue forecasts being adjusted by -1.5% over the past three months. During the same period, the stock price has changed by -11.18%.
arrow icon

How many employees does Amicus Therapeutics Inc (FOLD). have?

Amicus Therapeutics Inc (FOLD) has 499 emplpoyees as of July 20 2025.

arrow icon

What is Amicus Therapeutics Inc (FOLD) market cap?

Today FOLD has the market capitalization of 1.84B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free